Controlled release formulation having a preformed passageway
    1.
    发明授权
    Controlled release formulation having a preformed passageway 失效
    具有预制通道的控制释放制剂

    公开(公告)号:US5654005A

    公开(公告)日:1997-08-05

    申请号:US476455

    申请日:1995-06-07

    IPC分类号: A61K9/00 A61K9/22 A61K9/36

    CPC分类号: A61K9/0004

    摘要: A controlled release pharmaceutical tablet having at least one passageway, said tablet having:(a) a compressed core which comprises:(i) a medicament;(ii) an amount of a water soluble osmotic agent which is effective to cause the medicament to be delivered from said passageway in the presence of aqueous media;(iii) a water-swellable pharmaceutically acceptable polymer; and(b) a membrane coating around said core tablet which comprises a water insoluble pharmaceutically acceptable polymer.

    摘要翻译: 一种具有至少一个通道的控释药物片剂,所述片剂具有:(a)压缩芯,其包含:(i)药物; (ii)一定量的水溶性渗透剂,其有效地引起药物在水介质存在下从所述通道递送; (iii)水溶胀性药学上可接受的聚合物; 和(b)围绕所述芯片的膜包衣,其包含水不溶性的药学上可接受的聚合物。

    Controlled release formulation for water insoluble drugs in which a
passageway is formed in situ
    2.
    发明授权
    Controlled release formulation for water insoluble drugs in which a passageway is formed in situ 失效
    水不溶性药物的控制释放制剂,其中通道原位形成

    公开(公告)号:US5736159A

    公开(公告)日:1998-04-07

    申请号:US430356

    申请日:1995-04-28

    IPC分类号: A61K9/00 A61K9/28 A61K9/36

    摘要: A controlled release pharmaceutical tablet is disclosed which is based on: (a) a compressed core which contains: (i) a medicament; (ii) at least 23% to 55% by weight, based on the total weight of the core, of a water soluble osmotic agent; (iii) a water soluble pharmaceutically acceptable polymeric binder; (iv) a water-swellable pharmaceutically acceptable polymer; (v) a conventional pharmaceutical excipient; and (b) a membrane coating around said core tablet which consists essentially of: (i) a modified water insoluble pharmaceutically acceptable polymer; and (ii) a pharmaceutically acceptable water soluble polymer.

    摘要翻译: 公开了一种控释药物片剂,其基于:(a)压缩核心,其包含:(i)药物; (ii)基于芯的总重量的至少23重量%至55重量%的水溶性渗透剂; (iii)水溶性药学上可接受的聚合物粘合剂; (iv)水溶胀性药学上可接受的聚合物; (v)常规药物赋形剂; 和(b)围绕所述芯片的膜包衣,其基本上由以下组成:(i)改性的水不溶性药学上可接受的聚合物; 和(ii)药学上可接受的水溶性聚合物。

    Controlled release bupropion formulation
    3.
    发明授权
    Controlled release bupropion formulation 失效
    受控释放的安非他酮制剂

    公开(公告)号:US06210716B1

    公开(公告)日:2001-04-03

    申请号:US09259133

    申请日:1999-02-26

    IPC分类号: A61K914

    摘要: A controlled release dosage form of bupropion hydrochloride which comprises: (a) a first pellet having a core of bupropion hydrochloride and hydroxypropyl methylcellulose at a weight ratio of 10:1 to 30:1 and a coating of a mixture of an acrylic resin which is soluble in acidic media and ethyl cellulose; (b) a second pellet having a core of bupropion hydrochloride and hydroxypropyl methylcellulose at a ratio of 10:1 to 30:1; an inner coating of a mixture of an acrylic resin which is soluble in acidic media and a water insoluble polymer and an outer coating which comprises an enteric coating polymer.

    摘要翻译: 一种盐酸安非他酮的控释剂型,其包含:(a)具有核心的盐酸安非他酮和羟丙基甲基纤维素的重量比为10:1至30:1的第一颗粒和丙烯酸树脂的混合物的涂层,所述丙烯酸树脂是 可溶于酸性介质和乙基纤维素;(b)具有10:1至30:1比例的盐酸安非他酮核心和羟丙基甲基纤维素的第二粒料; 可溶于酸性介质的丙烯酸树脂和水不溶性聚合物的混合物的内涂层和包含肠溶衣聚合物的外涂层。

    Dosage forms comprising a short acting sedative-hypnotic or salt thereof
    10.
    发明申请
    Dosage forms comprising a short acting sedative-hypnotic or salt thereof 审中-公开
    包含短效镇静催眠药或其盐的剂型

    公开(公告)号:US20070286902A1

    公开(公告)日:2007-12-13

    申请号:US11448199

    申请日:2006-06-07

    IPC分类号: A61K31/4745 A61K9/22

    CPC分类号: A61K9/209 A61K31/4745

    摘要: In certain embodiments the invention is directed to an oral solid pharmaceutical dosage form comprising: a first portion of a short acting sedative-hypnotic in an release immediate release component; and a second portion of the sedative-hypnotic in a delayed component, the delayed release component comprising (i) a unitary core comprising the second portion of sedative-hypnotic dispersed in a controlled release matrix and (ii) a delayed release coating surrounding the core.

    摘要翻译: 在某些实施方案中,本发明涉及口服固体药物剂型,其包含:释放速释组分中的短效镇静催眠药的第一部分; 和延迟组分中的镇静催眠剂的第二部分,所述延迟释放组分包含(i)包含分散在控释基质中的第二部分镇静催眠剂的单一核心,和(ii)包围核心的延迟释放涂层 。